PUNE, India, Sept. 22, 2026 /PRNewswire/ -- The Global Exosomes Market was valued at USD 230.55 Million in 2025 and is projected to expand at a 28.8% CAGR from 2026 to 2034, reaching USD 2,250 Million by 2034, according to a new analysis by Maximize Market Research.

Global Exosomes Market

The Global Exosomes Market Report 2025 provides a detailed analysis of market trends, growth drivers, emerging technologies, competitive developments, and forecasts through 2034. Exosomes are nanosized extracellular vesicles released by cells that transport proteins, lipids, and genetic material between cells, supporting important biological communication processes. The market includes exosome-based products and technologies used across therapeutics, drug delivery, diagnostics, biomarker research, regenerative medicine, and other biomedical applications.

The growing focus on advanced drug delivery and precision medicine is supporting the development of exosome-based technologies. Increasing research into the biological functions of exosomes, rising investment in biotechnology, and advancements in isolation, characterization, and engineering technologies are encouraging pharmaceutical and biotechnology companies to expand their exosome-related pipelines. Their potential to serve as targeted delivery vehicles for therapeutic molecules is also creating new opportunities across drug development and regenerative medicine.

The expanding use of exosomes in diagnostics and biomarker research is further supporting market development as researchers explore their potential for disease detection and monitoring. Companies and research institutions are increasingly focusing on engineered exosomes, scalable manufacturing, and clinical applications to address the growing demand for advanced cell-free therapeutic solutions. These developments, combined with increasing R&D activity and expanding applications across healthcare and life sciences, are expected to strengthen the global exosomes market landscape.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/189733/

Global Exosomes Market gains momentum as advanced drug delivery, regenerative medicine, and expanding biotechnology research accelerate innovation: Maximize Market Research unveils key insights.

Global Exosomes Market Size & Forecast:

Global Exosomes Market Trends & Insights

- North America leads the Global Exosomes Market, supported by advanced biotechnology, strong pharmaceutical R&D, and growing clinical research in exosome-based therapeutics and diagnostics.

- Asia-Pacific is emerging as a high-growth region, driven by increasing biotechnology investment, healthcare expenditure, and research into extracellular vesicle technologies.

- Exosome-based drug delivery and regenerative medicine are gaining traction due to their potential in targeted therapies, tissue repair, and cell-free treatment approaches.

- Exosome diagnostics and biomarker research are expanding, particularly for disease detection, monitoring, liquid biopsy, and personalized medicine.

- Advances in exosome isolation, purification, characterization, and engineering are improving scalability and supporting wider therapeutic and clinical applications.

Advanced Drug Delivery and Therapeutic Applications Drive Market Growth

The expanding use of exosomes in drug delivery, regenerative medicine, diagnostics, and therapeutic development is driving market growth. Increasing biotechnology R&D, clinical research, and investment in exosome-based therapeutics are encouraging pharmaceutical and biotechnology companies to explore exosomes as carriers for drugs, proteins, RNA, and other biomolecules.

High Development Costs and Manufacturing Complexity Restrain Market Growth

High R&D costs, complex exosome isolation and purification processes, manufacturing challenges, and limited standardization can restrict wider commercialization. Variations in exosome quality, characterization methods, scalability, and regulatory requirements also create challenges for companies developing exosome-based products and extracellular vesicle technologies.

Exosome-Based Therapeutics and Diagnostics Create Opportunities

Growing research into engineered exosomes, targeted drug delivery, biomarkers, liquid biopsy, regenerative medicine, and cell-free therapies is creating new market opportunities. Advances in exosome engineering, characterization, and therapeutic development are supporting applications across drug development, disease diagnosis, and personalized medicine.

Standardization and Regulatory Challenges Create Barriers

Limited standardization in exosome isolation, characterization, manufacturing, quality control, and clinical evaluation remains a key challenge. Differences in production methods and regulatory requirements can affect the consistency, safety, and scalability of exosome-based therapeutics and diagnostics, encouraging industry players to develop more reliable and standardized technologies.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/189733/

Global Exosomes Market Segmentation Insights

The Global Exosomes Market is segmented by Product, Application, Indication, and End User. Increasing research into exosome-based therapeutics, drug delivery, diagnostics, regenerative medicine, and biomarker applications, along with advances in extracellular vesicle technologies, is supporting market development across these segments.

North America Leads the Exosomes Market While Asia Pacific Emerges as a High-Growth Region

North America holds a significant position in the Global Exosomes Market, supported by advanced biotechnology infrastructure, strong pharmaceutical and life sciences R&D, high investment in extracellular vesicle research, and increasing clinical development of exosome-based therapeutics and diagnostics. The United States represents a major market due to its strong biotechnology ecosystem and expanding applications of exosomes in drug delivery, biomarker discovery, regenerative medicine, and personalized medicine. Canada also contributes through increasing biomedical research and adoption of advanced life sciences technologies.

Europe represents an important market, supported by established healthcare and biotechnology infrastructure, research funding, and growing interest in exosome isolation, characterization, engineering, and therapeutic applications. Germany, the United Kingdom, France, Italy, and Spain are key contributors, with pharmaceutical companies and research institutions advancing extracellular vesicle technologies, diagnostics, drug delivery, and regenerative medicine.

Asia Pacific is expected to witness strong growth as biotechnology capabilities expand and investment in life sciences, cell-free therapies, and advanced drug delivery technologies increases. China, Japan, India, South Korea, and Australia are important markets, supported by expanding pharmaceutical R&D, increasing healthcare expenditure, and growing research into exosome-based therapeutics, diagnostics, biomarker research, and regenerative medicine.

Middle East & Africa is gradually developing as investments in healthcare infrastructure, biotechnology research, and advanced diagnostic technologies increase. The UAE, Saudi Arabia, Israel, and South Africa are contributing through growing interest in precision medicine, molecular diagnostics, regenerative medicine, and emerging extracellular vesicle applications.

South America is supported by improving healthcare infrastructure, expanding biotechnology research, and increasing adoption of advanced diagnostic and therapeutic technologies. Brazil represents an important regional market, while Argentina, Chile, and Colombia are contributing as research capabilities and access to innovative biomedical and exosome-based technologies continue to develop.

Leading Companies Strengthen the Exosomes Technology and Therapeutics Landscape

Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Lonza Group Ltd., and System Biosciences, LLC are among the prominent companies contributing to the exosome and extracellular vesicle technology landscape. Their activities across exosome isolation, purification, characterization, research tools, and bioprocessing solutions are supporting advancements in exosome research and commercialization. The market is also attracting biotechnology companies focused on engineered exosomes, targeted drug delivery, regenerative medicine, and exosome-based therapeutics.

Global Exosomes Market Competitive Landscape

The Global Exosomes Market is highly research-oriented and technology-driven, with companies focusing on exosome isolation and purification technologies, characterization platforms, engineered exosomes, drug delivery systems, biomarker discovery, diagnostics, regenerative medicine, and therapeutic development. Key players include Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Lonza Group Ltd., System Biosciences, LLC, QIAGEN N.V., Bio-Techne Corporation, and NanoView Biosciences, Inc., alongside emerging biotechnology companies specializing in extracellular vesicle applications. Competition is shaped by R&D investment, technology innovation, product development, strategic collaborations, clinical research, manufacturing capabilities, and expansion into therapeutic and diagnostic applications.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/189733/

Exosomes Market, Key Players:

- Thermo Fisher Scientific Inc.

- Danaher Beckman Coulter

- QIAGEN N.V.

- Lonza Group Ltd.

- Hitachi Chemical Co., Ltd.

- Merck KGaA

- Sistemic Ltd.

- System Biosciences, LLC

- Bio-Techne Corporation

- AMS Biotechnology Ltd.

- NanoFCM

- NX Prenatal Inc.

LEBANON, Ore., Sept. 22, 2026 /PRNewswire/ -- Western University of Health Sciences Heatherington College of Osteopathic Medicine (WesternU HCOM) was pleased to host the second annual A.P. Howells, DO, Endowed Lectureship Aug. 29-30, 2026.

The lectureship featured a hands-on introduction to the Fascial Distortion Model (FDM) to evaluate and treat common musculoskeletal conditions. The lectureship combined online learning, interactive demonstrations, and supervised practice to help participants recognize key distortion patterns and apply introductory treatment techniques in patient care.

The workshop was led by Todd Capistrant, DO. Capistrant teaches FDM nationally and is a physician with Foundation Health Partners where he has been serving as a Medical Director since 2013. He specializes in family medicine and osteopathic manipulative medicine (OMM) and is family practice board certified by the American Board of Family Medicine and the American College of Osteopathic Family Physicians. He currently practices OMM full-time.

"When teaching the FDM we are hoping that the participants will begin to look at patients as the expert and watch the pain gesture, listen to the patients' explanation of pain, and apply their toolkit to address fascial distortions. When attendees employ their own skills in the model, we routinely see excellent results and rapid improvement for patients. Helping patients stay active is one of my top priorities. We know that being able to be active is the best predictor of long-term health," said Capistrant. "I strongly feel that OMM is one of the most powerful tools that DOs have to help our patients stay healthy. Addressing the structure and function of patients, reducing pain, and improving their ability to stay active is one of the most powerful medicines we have. The osteopathic toolkit is invaluable at helping our patients achieve these goals. We know that remaining active is more powerful than any medication at reducing the risk of heart disease, stroke, dementia, and many cancers. If we use our toolkit to include FDM, we are helping patients help themselves by reducing the risk of disease and preventing illness."

The lectureship also offered a unique opportunity to reflect on the history and legacy of osteopathic medicine in Oregon. The lectureship honors Allen Page "A.P." Howells, DO, a pioneer of osteopathic medicine in Oregon. Howells was drawn to osteopathy after receiving treatment from an early osteopath that transformed his health. After graduating from A.T. Still College of Osteopathic Medicine in Kirksville, Missouri, in 1911, Howells moved to Oregon to begin his practice. At the time, osteopathic medicine was still establishing its place within the state's health care system. Howells served patients in and around the Willamette Valley for more than 50 years, eventually establishing a clinic in downtown Albany. His career was marked by a commitment to holistic patient-centered care.

"He was a general practitioner, that's what they were called back in the day. He was trained to do everything and he did everything. He delivered babies, he performed minor surgeries, and he did anesthesia for other surgeons," said Howells's daughter, Jocelyn Howells. "I would walk from high school to his office to do my homework in the back room and wait for him to leave the office and then I would ride around with him on his house calls, because we didn't go home until he was done. And I remember seven or eight o'clock at night sometimes I wouldn't get home because he was seeing a lot of patients. He would drive over to Lebanon, Scio, Crabtree, all those little towns around to serve people that couldn't get in to see him. He was so focused on service, taking care of his patients. And if they couldn't pay, he didn't worry about it."

On Saturday, Aug. 29, WesternU HCOM hosted the inaugural Shoulders of Giants Endowed Lectureship Dinner, celebrating Dr. Howells' legacy and recognizing osteopathic physicians and students who continue to advance the profession. The evening also celebrated the osteopathic medicine trailblazer Mary Howells, DO. Dr. Mary Howells earned her osteopathic medical degree from A.T. Still College of Osteopathic Medicine in Kirksville, Missouri, and practiced alongside her brother, Dr. A.P. Howells, in Corvallis before pursuing psychiatry and establishing her own practice in Portland.

The evening also marked the establishment of the John Stiger, DO, Student Champion of Osteopathic Medicine Award, designated and gifted by Jocelyn Howells in honor of Dr. Stiger's extraordinary commitment to supporting, mentoring and championing future osteopathic physicians. A family medicine physician in the Portland area, Dr. Stiger has devoted his professional career to caring for patients and advancing the principles and values of osteopathic medicine.

Three individuals were honored for their leadership and dedication: Micah Thorp, DO, received the inaugural A.P. Howells, DO, Leadership Legacy in Osteopathic Medicine Award; Maggie Doe, DO, received the inaugural Mary Howells, DO, Vanguard Women in Osteopathic Medicine Award; and WesternU HCOM fourth-year student Alissa Reed received the inaugural John Stiger, DO, Student Champion of Osteopathic Medicine Award.

"The A.P. Howells, DO, Endowed Lectureship provides an opportunity to recognize that the story of osteopathic medicine has always been shaped by pioneers, women and men who saw possibilities where others saw limitations, who understood that healing requires both scientific excellence and human compassion, and who advanced that vision with courage and conviction. We are here today because of those pioneers, and because of those who continue to inspire, mentor, and elevate others in service to that mission," said WesternU HCOM Site Dean Heather Phipps, DO, MBA, FAAOS. "This lectureship would not have been possible without Jocelyn Howells and the Howells family. Their legacy in Oregon is deeply woven into the fabric of community health, education, and service. Through their enduring commitment to osteopathic medicine and their belief in our collective responsibility to prepare future generations of physicians, they have created a lasting impact that continues to benefit communities across the region."

About Western University of Health Sciences

About Western University of Health Sciences Western University of Health Sciences (www.westernu.edu), located in Lebanon, Oregon and Pomona, Calif., is an independent nonprofit health professions university, conferring degrees in osteopathic medicine, physical therapy, biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, pharmacy, physician assistant studies, podiatric medicine, and veterinary medicine. WesternU is home to WesternU Health, where the best in collaborative health care services is offered.

SOURCE Western University of Health Sciences (WesternU)

Share this article

ORLANDO, Fla., Sept. 22, 2026 /PRNewswire/ -- United Parks & Resorts Inc. (NYSE: PRKS), a leading theme parks and entertainment company, today announced the promotion of Kyle Miller to President and Scott Maupin to Chief Parks Operating Officer, effective September 22, 2026.

In his new role, Miller will work closely with Chief Executive Officer Marc Swanson and the executive leadership team to advance the Company's growth strategy, operational priorities and commitment to delivering memorable guest experiences across its portfolio of parks.

"We are excited to announce Kyle's promotion to President. Kyle is a highly respected leader with deep operational expertise, and a proven ability to drive results," said Swanson. "Having spent more than three decades growing his career within our organization, Kyle has a unique understanding of our business, our culture, and our commitment to delivering experiences that matter. His leadership will be instrumental as we continue executing our growth strategy and creating value for our guests, team members, partners and shareholders."

Since joining the executive leadership team as Chief Parks Operations Officer, Miller has been responsible for overseeing operations across the Company's park portfolio. Previously, Miller served as Park President of SeaWorld Orlando, Discovery Cove and Aquatica Orlando, where he helped lead some of the Company's most successful operational and guest experience initiatives. Miller began his career with Busch Entertainment Corporation in 1995 and has served in a variety of leadership positions across the Company's operations, culinary, merchandise and park management functions.

"As I step into this new role, I am honored and excited by the opportunity to help lead United Parks into its next chapter," said Miller. "Our parks have a unique ability to bring families together, inspire guests through extraordinary experiences, and advance our mission of animal care, conservation and rescue. I look forward to working alongside our talented ambassadors and leadership team to build on the growth opportunities across our business."

Following Miller's promotion, Scott Maupin will assume the role of Chief Parks Operating Officer. Maupin previously served as Co-Chief Parks Operating Officer of United Parks & Resorts.

"Since joining United Parks, Scott has quickly established himself as a strong and effective leader," Swanson said. "He brings significant operational experience and a clear focus on execution, performance and the guest experience. We are pleased to have him step into this expanded role and look forward to his continued contributions as we execute against our priorities across the portfolio."

Maupin joined United Parks & Resorts in May 2026 as Co-Chief Parks Operating Officer, bringing more than 30 years of experience across theme park, resort and hospitality operations. Prior to joining the Company, he served as Senior Vice President and Managing Director for Merlin Entertainments, where he led its North American portfolio of 45 entertainment destinations. Earlier in his career, Maupin held senior leadership roles with Great Wolf Resorts and Six Flags.

"I'm excited to take on this expanded role and continue working alongside our teams across the Company," Maupin said. "Over the past several months, I have had the opportunity to see firsthand the passion our teams bring to our parks every day. I look forward to building on that foundation as we continue delivering exceptional experiences for our guests and driving operational excellence across the business."

The Company also announced that Christopher Finazzo, Chief Commercial Officer, will depart United Parks & Resorts to pursue new opportunities. United Parks thanks Finazzo for his contributions during his tenure and wishes him well in his next chapter.

About United Parks & Resorts Inc.

United Parks & Resorts Inc. (NYSE: PRKS) is a global theme park and entertainment company that owns or licenses a diverse portfolio of award-winning park brands and experiences, including SeaWorld®, Busch Gardens®, Discovery Cove, Sesame Place®, Water Country USA, Adventure Island, and Aquatica®. The Company's seven world-class brands span 13 parks in seven markets across the United States and Abu Dhabi, offering experiences that matter with exhilarating thrill and family-friendly rides, coasters, and experiences, inspiring up-close and educational presentations with wildlife, and other various special events throughout the year. In addition, the Company collectively cares for one of the largest zoological collections in the world, is a global leader in animal welfare, training, and veterinary care, and is one of the leading marine animal rescue organizations in the world with a legacy of rescuing and caring for animals that spans over 60 years, including coming to the aid of over 43,000 animals in need. To learn more, visit United Parks & Resorts.

Copies of this and other news releases as well as additional information about United Parks & Resorts Inc. can be obtained online at United Parks & Resorts. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail by registering at that website.

CONTACT:

Investor Relations:

Matthew Stroud

Investor Relations

888-410-1812

[email protected]

Media:

AnneMarie Iturrizaga

United Parks & Resorts Inc.

[email protected] 

SOURCE United Parks and Resorts Inc.

Share this article

Authorization enables Chainguard to assign CVEs for qualifying open source vulnerabilities processed through Athena, helping protect open source software from AI attacks

NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Chainguard, the trusted source for open source, today announced that it has been authorized by the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA). The mission of the CVE Program is to identify, define, and catalog publicly disclosed cybersecurity vulnerabilities. As a CNA, Chainguard can assign CVE identifiers and publish CVE Records for qualifying vulnerabilities. The authorization is scoped to include open source vulnerabilities processed through the Athena coalition, when upstream maintainers have already fixed the flaw without an identifier, no maintainer remains to assign one, or no more specific CNA covers the project.

This milestone underscores Chainguard's deep commitment to transparent, coordinated vulnerability disclosure and protecting open source software from AI attacks. Frontier AI models are surfacing latent vulnerabilities in widely used open source software that traditional security tools and years of expert review failed to detect. As AI compresses the time between discovery and exploitation, vulnerabilities without CVE identifiers may remain invisible to the scanners, databases, and compliance systems organizations rely on to identify and prioritize risk.

"AI-driven zero-day discovery is pushing traditional approaches to vulnerability handling and disclosure to the breaking point," said Quincy Castro, Chief Information Security Officer, Chainguard. "Through Athena, we are working to get fixes as quickly as possible into as many hands as possible. Becoming a CNA allows us to communicate about vulnerability fixes in a 'language' familiar to many organizations and open source maintainers."

The designation strengthens Athena, Chainguard's industry coalition for the orchestrated defense of open source software, by providing precise affected and fixed version ranges and technical details that help organizations assess their exposure, reduce false positives, and take appropriate action. Chainguard's CVE Records also defer to maintainers and project-specific CNAs wherever they exist. With the help of coalition members and mitigation partners, such as Akamai, BNY, Cisco, Cloudflare, JPMorganChase, Kyndryl, Morgan Stanley, and Upwind, Athena validates AI-discovered vulnerabilities, and develops fixes, then partners with Akrites to carry vulnerabilities through disclosure and toward durable upstream remediation.

To learn more about how Chainguard advances open source vulnerability discovery through Athena, visit chainguard.dev/athena.

About Chainguard

Chainguard is the trusted source for open source. By providing engineers and AI agents with hardened, trusted, and production-ready artifacts, Chainguard helps organizations prevent AI supply chain attacks, increase engineering velocity while reducing toil, and maintain continuous compliance. Customers include Fortune 500 enterprises and global industry leaders, including Anduril, Canva, DocuSign, OpenAI, Public Storage, Snap Inc., and Snowflake. Chainguard is venture-backed by leading investors, including Amplify, IVP, Kleiner Perkins, Lightspeed Venture Partners, Mantis VC, Redpoint Ventures, Sequoia Capital, and Spark Capital. For more information, visit: https://www.chainguard.dev/

Brittany Hendrickson, [email protected]

SOURCE Chainguard

Share this article

Partnership marks an important step in OxiWear's international expansion and growing presence in the Middle East

ARLINGTON, Va. and DOHA, Qatar, Sept. 22, 2026 /PRNewswire/ -- OxiWear Inc., a wearable technology company focused on continuous physiological measurements, today announced an exclusive distribution partnership with Alfardan Medical with Northwestern Medicine (AMNM) in Qatar.

The partnership brings together OxiWear's wearable measurement technology with AMNM's established presence, local expertise, and network in Qatar, supporting OxiWear's continued expansion across the Middle East.

The partnership marks another milestone in OxiWear's international growth as the company continues to expand its technology and build strategic relationships across the United States and international markets.

"Qatar has built an incredible ecosystem around technology and innovation, and we are excited to partner with AMNM as we continue expanding OxiWear internationally," said Shavini Fernando, Founder and CEO of OxiWear. "Having a strong local partner that understands the market and shares our long-term vision is incredibly important to us. We see significant opportunities for OxiWear in Qatar and across the region, and we look forward to working closely with Dr. Abdulla and the AMNM team to build that presence."

Under the partnership, the organizations will collaborate on distribution, market development, customer engagement, and opportunities for OxiWear across Qatar.

"We are pleased to partner with OxiWear and support the company's expansion into Qatar," said Dr. Abdulla Al-Ansari, CEO of AMNM. "Innovation and the introduction of new technologies are important to the continued development of Qatar's ecosystem. OxiWear's approach to continuous physiological measurements presents exciting opportunities across a range of applications, and we look forward to working together to establish and grow its presence in Qatar."

The partnership is part of OxiWear's broader international expansion strategy and reflects the company's focus on establishing strong local relationships as it enters and develops new markets.

About OxiWear: OxiWear Inc. is a wearable technology company developing solutions for continuous physiological measurements. Through its wearable technology and connected platform, OxiWear is building new ways to capture physiological data continuously across a range of environments and applications. Headquartered in Arlington, Virginia, OxiWear works with organizations and partners in the United States and internationally across research, performance, industrial, and other markets.

For more information, visit oxiwear.com.

Alfardan Medical with Northwestern Medicine (AMNM) is a multi-specialty private day-care surgery center located in Lusail, Qatar, operating in affiliation with Northwestern Medicine, the Chicago-based academic health system. AMNM brings together internationally trained physicians, advanced surgical facilities, and Northwestern Medicine's clinical standards to deliver high-quality, patient-centered outpatient care across a wide range of specialties. Committed to innovation and clinical excellence, AMNM works to introduce new medical technologies and best practices that advance healthcare in Qatar and the wider region.

SOURCE OxiWear

Share this article

MONTREAL and SAN FRANCISCO, Sept. 22, 2026 /PRNewswire/ -- Coveo (TSX: CVO), the leader in AI-Relevance, delivering best-in-class search and generative experiences, today announced the voting results for its annual general meeting of shareholders held on September 22, 2026 (the "Meeting"). The detailed results of the votes held at the Meeting are set out below.

Election of Directors

According to votes received, each of the following seven (7) nominees was duly elected as a director of the Corporation until the next annual meeting of shareholders, or until such person's successor is elected or appointed, with the following results:

Appointment of Auditors

According to votes received, PricewaterhouseCoopers LLP were duly appointed as auditors of the Corporation for the ensuing year, at a remuneration to be fixed by the board of directors of the Corporation, with the following results:

About Coveo

Coveo brings superior AI-Relevance to every point-of-experience, transforming how enterprises connect with their customers and employees to maximize business outcomes.

Relevance is about moving from persona to person, the degree to which the enterprise-wide content, products, recommendations, and advice presented to a person online aligns easily with their context, needs, preferences, behavior and intent, setting the competitive experience gold standard. Every person's journey is unique, and only AI can solve the complexity of tailoring experiences across massive, diverse audiences and large volumes and variety of content and products.

Stay up to date on the latest Coveo news and content by subscribing to the Coveo blog, and following Coveo on LinkedIn, X, and YouTube.

SOURCE Coveo Solutions Inc.

Share this article

TRAVERSE CITY, Mich., Sept. 22, 2026 /PRNewswire/ -- RADwood, driven by Hagerty and presented by Goodyear, returns to the San Francisco Bay Area on Saturday, October 24, for its most engaging event yet. The automotive festival known for celebrating the cars and culture of the '80s and '90s will stage the brand's first free-to-attend evening event and feature iconic cars at full-throttle in its latest, enthusiast-focused format.

All the details car enthusiasts need to get totally rad:

- What: New free-to-attend RADwood format featuring Wheels in Motion, a full-throttle demonstration set against the backdrop of the San Francisco skyline

- When: Saturday, October 24, 2026; 4 p.m. to 8 p.m.

- Where: Gold Bar Hangar, Alameda, CA

- Tickets: Free attendance with registration – a $25 value!

"RADwood exists because driving enthusiasts crave real experiences and community," said Hagerty CMO Marc Burns. "For 2026, we cranked it up! We added iconic cars running at full-throttle, a new evening format and then made it free to attend. It's everything you love about the '80s and '90s, minus the dial-up."

Presented by Goodyear, the show will feature hundreds of period-correct cars, trucks and motorcycles onsite at Gold Bar Hangar at historic Alameda Point. Wheels in Motion, a driving exhibition including the era's most significant rides performing flybys at full-throttle, will present a rare opportunity to see and hear some of the greatest cars at redline. Pioneer will provide period tunes as official sound partner of RADwood NorCal.

Featured vehicle classes include Kei Cars, Tuners, Movie Cars and Mustang vs. Camaro. Additionally, for the first time, RADwood expands into Y2K with the introduction of a new class, 'Millenia,' spotlighting iconic cars from 2000–2010. Rounding out the entertainment and hospitality are popular Bay Area food trucks and RADwood's signature Raddest Dressed contest, where attendees are judged on their period-correct attire.

Celebrity guest appearances and enthusiast-focused content are expected to be announced in the coming weeks.

The show runs from 4:00 to 8:00 p.m., with early entry for Hagerty Drivers Club members at 3:00 p.m. Admission is free, with all attendees asked to reserve a ticket in advance. Show car owners and entrants are invited to register their vehicle on the RADwood website.

About RADwood

RADwood is the OG celebration of '80s and '90s cars and culture, blending period correct dress with automotive awesomeness. Originally a nationwide event for cars, trucks and bikes from 1980-1999, RADwood now welcomes cars from the Y2K era in its Millenia class. Driving enthusiasts can find RADwood at The Amelia Concours, The Greenwich Concours, Motorlux and more where they can capture the essence of a bodacious era.

About Hagerty (NYSE: HGTY)

Hagerty is a company built by drivers for drivers, protecting 3 million vehicles in the United States, Canada and the UK. We make it easier and more enjoyable for car enthusiasts to drive and celebrate the machines they love through innovative vehicle insurance products, live and digital auctions, engaging media and events and the Hagerty Drivers Club, the world's largest membership community of car lovers. For more information, please visit www.hagerty.com or www.newsroom.hagerty.com. Never Stop Driving®.

SOURCE Hagerty

Share this article

PUNE, India, Sept. 22, 2026 /PRNewswire/ -- The Global Lupus Nephritis Market was valued at USD 1.96 Billion in 2025 and is projected to expand at an 8.5% CAGR from 2026 to 2034, reaching USD 4.08 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Lupus Nephritis Market

The Global Lupus Nephritis Market Report 2025 provides a detailed analysis of market trends, growth drivers, competitive developments, and forecasts through 2034. Lupus nephritis is a serious renal complication of systemic lupus erythematosus (SLE), in which immune-system dysfunction causes inflammation and damage to the kidneys. The market includes immunosuppressive therapies, biologic therapies, corticosteroids, targeted treatments, and other therapeutic approaches used to control disease activity, prevent kidney damage, and improve patient outcomes.

The growing focus on early diagnosis and effective disease management is supporting advances in lupus nephritis treatment. Increasing awareness of SLE-related kidney complications, improvements in diagnostic approaches, and the development of targeted therapies are encouraging pharmaceutical companies to expand their treatment portfolios. The adoption of biologic and novel therapies is also creating opportunities for more personalized approaches to managing patients with lupus nephritis.

The need for effective long-term treatment is further supporting market development as lupus nephritis can lead to progressive kidney damage and, in severe cases, kidney failure. Pharmaceutical companies are therefore focusing on novel drug development, targeted immune therapies, clinical research, and improved treatment strategies to address unmet needs across different stages of the disease. These developments, combined with rising healthcare expenditure and increasing emphasis on early intervention, are expected to strengthen the global lupus nephritis treatment landscape.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/187839/

Global Lupus Nephritis Market gains momentum as targeted therapies, rising disease awareness and advances in kidney disease management reshape treatment strategies: Maximize Market Research unveils key insights.

Global Lupus Nephritis Market Size & Forecast:

Global Lupus Nephritis Market Trends & Insights

- North America is a leading region in the Global Lupus Nephritis Market, supported by advanced healthcare infrastructure, strong pharmaceutical research capabilities, higher awareness of autoimmune diseases, and the availability of innovative treatment options.

- Europe represents a significant market, driven by increasing focus on early diagnosis and disease management, established healthcare systems, and growing adoption of biologic and targeted therapies for lupus nephritis.

- Targeted and biologic therapies are gaining importance as pharmaceutical companies focus on treatments that address specific immune pathways involved in lupus nephritis and offer improved disease management.

- Early diagnosis and long-term disease management are becoming increasingly important as healthcare providers emphasize controlling kidney inflammation, preventing disease progression, and reducing the risk of severe renal complications.

- Growing clinical research and novel drug development are reshaping the treatment landscape, with companies investing in advanced immunosuppressive therapies, biologics, and emerging treatment approaches to address unmet needs among lupus nephritis patients.

Rising Disease Burden and Treatment Advances Drive Market Growth

The increasing burden of systemic lupus erythematosus (SLE) and its renal complications is strengthening demand for effective lupus nephritis treatments, while advances in targeted therapies, biologics, early diagnosis, and precision disease management are reshaping the treatment landscape. Pharmaceutical companies are expanding their pipelines with novel therapies aimed at controlling immune-mediated kidney inflammation, preventing disease progression, and improving long-term patient outcomes.

High Treatment Costs and Complex Disease Management Restrain Market Growth

The high cost of advanced therapies, prolonged treatment requirements, and the need for continuous clinical monitoring can limit access to lupus nephritis treatment and restrain broader market adoption. Treatment complexity and differences in patient response also create challenges for healthcare providers and pharmaceutical companies, particularly as patients may require long-term immunosuppressive therapy and careful management of treatment-related risks.

Targeted Therapies and Novel Drug Development Create Opportunities

The growing development of targeted and biologic therapies is creating significant opportunities in the lupus nephritis market as pharmaceutical companies focus on specific immune pathways involved in disease progression. Increasing clinical research, innovative drug pipelines, and greater emphasis on personalized treatment are supporting the development of therapies designed to improve disease control, protect kidney function, and address unmet treatment needs.

Treatment Safety and Variable Patient Response Create Challenges

Variable responses to existing therapies, treatment-related safety concerns, and the complexity of long-term immunosuppression remain important challenges in lupus nephritis management. These factors are encouraging pharmaceutical companies to invest in novel mechanisms of action, targeted therapies, and improved treatment strategies that can provide sustained disease control while reducing treatment-related risks and improving patient outcomes.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/187839/

Global Lupus Nephritis Market Segmentation Insights

The Global Lupus Nephritis Market is segmented by Drug Class, Treatment Type, Route of Administration, and Distribution Channel. Increasing demand for effective disease management, growing adoption of targeted and biologic therapies, and continued development of novel treatment approaches are influencing market expansion across these segments.

North America Leads the Lupus Nephritis Market While Europe and Asia Pacific Strengthen Growth

North America holds a significant position in the Global Lupus Nephritis Market, supported by advanced healthcare infrastructure, strong autoimmune disease research, high treatment awareness, and the availability of innovative therapies. The United States represents a major market due to its established pharmaceutical industry, increasing adoption of biologic and targeted treatments, and strong clinical research activity, while Canada contributes through its developed healthcare system and growing focus on autoimmune disease management.

Europe represents a mature lupus nephritis treatment market, supported by established healthcare systems, increasing emphasis on early diagnosis, and continued development and adoption of advanced therapies. Germany, the United Kingdom, France, Italy, and Spain are important contributors to regional demand, with pharmaceutical companies and research institutions focusing on novel treatments and improved long-term disease management.

Asia Pacific is expected to witness strong growth as awareness of lupus and its renal complications increases, healthcare infrastructure improves, and access to advanced treatment options expands. China, Japan, India, South Korea, and Australia represent important markets, supported by growing healthcare expenditure, expanding pharmaceutical capabilities, and increasing focus on autoimmune disease diagnosis and treatment.

Middle East & Africa is developing gradually as healthcare infrastructure, specialist medical services, and awareness of autoimmune diseases improve. Countries such as Saudi Arabia, the UAE, Israel, and South Africa are contributing to regional demand through investments in healthcare services and access to specialized treatments.

South America is supported by improving healthcare access, increasing disease awareness, and the gradual expansion of advanced treatment options for autoimmune and renal disorders. Brazil represents an important regional market, while Argentina, Chile, and Colombia contribute to demand as diagnostic capabilities and access to specialized healthcare services continue to develop.

Pfizer, AstraZeneca and Merck & Co. Strengthen the Lupus Nephritis Treatment Landscape

Pfizer Inc., AstraZeneca PLC, and Merck & Co., Inc. are among the prominent pharmaceutical companies involved in the broader lupus and autoimmune disease treatment landscape, alongside other companies developing immunosuppressive, biologic, and targeted therapies. Their research and development activities, clinical programs, and expanding treatment portfolios are contributing to innovation in lupus nephritis management. The market is also influenced by companies developing novel mechanisms of action designed to improve disease control and address unmet treatment needs.

Global Lupus Nephritis Market Competitive Landscape

The Global Lupus Nephritis Market is competitive and innovation-driven, with pharmaceutical companies focusing on novel drug development, targeted immune therapies, biologics, clinical trials, and expansion of treatment portfolios. Key players include Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson, and other pharmaceutical companies involved in lupus and autoimmune disease therapeutics. Competition is shaped by clinical development, regulatory approvals, product innovation, strategic collaborations, and investments in therapies designed to improve treatment response and long-term kidney outcomes.

NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Forge, advised by JEGI LEONIS and a portfolio company of Apollo, has agreed to acquire Becker's Healthcare, a portfolio company of Pamlico Capital.

Headquartered in Chicago, Becker's Healthcare is a leading media and events platform serving hospital, health system and healthcare executives. Through its digital products, executive communities and live events, Becker's reaches over 1.5 million leaders and executives via its digital products and welcomes more than 15,000 attendees across its live events each year. It's an audience spanning nearly every seat at the healthcare leadership table, built by a team committed to growth, focus, and initiative.

Forge is the B2B events and media company formed by the combination of Emerald and Questex, after the acquisition by Apollo in July 2026. Forge's acquisition of Becker's will significantly expand its presence in healthcare and life sciences by bringing Becker's together with its existing healthcare portfolio, Fierce Healthcare and Life Sciences ("Fierce"). The combination of Becker's and Fierce will create a scaled 365-day omnichannel platform reaching key decisionmakers across the majority of the healthcare ecosystem, spanning the value chain from biotech, pharma to hospitals, health systems and payers, through over 35 live events, trusted media, digital products, newsletters, podcasts and year-round executive communities. The acquisition also reflects Forge's strategy to build scale and depth in markets with strong secular tailwinds, where the underlying industries are growing, and the need for trusted communities, content and connections is growing with them.

About JEGI LEONIS

JEGI LEONIS is a pre-eminent M&A advisory firm for the global technology, media, and business services industries. We advise founders, investors, and global corporations on a range of transactions, including buy-side and sell-side M&A, recapitalizations, divestitures, and debt advisory solutions. Headquartered in New York, our global team of over 80 professionals provides deep sector expertise which enhances the tailored support for each client and drives overall value. For more information, please visit www.JL-co.com.

Kelsey Haar, Chief Marketing Officer, JEGI LEONIS, (212) 754-0710

SOURCE JEGI LEONIS

Share this article

New three-pillar program gives systems integrators, MSSPs, resellers, and technology partners deal registration, co-sell support, tiered margins, and white-label delivery on Siemba's AI-driven CTEM platform

ATLANTA, Sept. 22, 2026 /PRNewswire/ -- Siemba, a leading continuous offensive security provider, today announced Siemba Pride, its formal global partner program for organizations that deploy, resell, or integrate with the Siemba platform.

Siemba Pride is built around three partner pillars. Enablers are systems integrators that deploy and operationalize Siemba within enterprise environments. Amplifiers are MSSPs, agencies, resellers, and procurement networks that bring Siemba to new customers through their own channels. Enhancers are ISVs and technology platforms that integrate with the Siemba ecosystem through APIs and co-engineered workflows.

Partners register deals to activate co-sell support and earn tiered margins across four levels: Registered, Silver, Gold, and Platinum. White-label delivery is available to Amplifier partners at Silver tier and above. Tier requirements, margin structure, and incentive programs are published in the Siemba Partner Portal.

"Siemba Pride is a shared growth platform. Partners expand their services, customers gain continuous adversarial exposure visibility, and trust is built through measurable outcomes," said Kiran Elengickal, VP of Global Alliances & Business Development at Siemba. "When partners succeed, customers stay safer, and that is how security should scale."

Partners joining Siemba Pride receive a demo environment provisioned typically within 24 hours of signing, co-branded sales kits, pitch decks, and technical demos, and a dedicated Partner Success Manager alongside a Solutions Engineer for technical pre-sales support. Siemba is already delivered to enterprise customers through global systems integrators, Big 4 consultancies, distribution networks, and hyperscaler marketplaces.

Organizations interested in joining Siemba Pride can register at partners.siemba.io/register. More information about the program is available at siemba.io/partners.

About Siemba

Siemba combines attack surface mapping, autonomous dynamic testing, AI-driven vulnerability assessment, and expert-led penetration testing into one continuous program. Its certified in-house pentesters are trusted by the Big 4, and every fix is revalidated automatically on the platform and expert-signed on engagements. Siemba covers web, mobile, cloud, and AI systems including large language models and AI agents. Headquartered in Alpharetta, Georgia, Siemba has been named a Sample Vendor in the Gartner® Hype Cycle™ for Application Security, the Gartner Hype Cycle for Security Operations, and the Gartner Hype Cycle for XaaS (Everything as a Service) in 2024, 2025 and 2026.

SOURCE Siemba

Share this article